PRESS RELEASE published on 01/31/2025 at 10:00, 1 year 3 months ago Bilan Semestriel Contrat de Liquidité Bilan semestriel du Contrat de Liquidité avec Gilbert Dupont. AURES Technologies confie la liquidité à la Société de Bourse, moyens au 31/12/2024 : actions 2 747, espèces 8 451,38 € Contrat De Liquidité Bilan Semestriel Gilbert Dupont AURES Technologies ADVANTECH-AURES
PRESS RELEASE published on 12/20/2024 at 17:55, 1 year 5 months ago AURES: Projet de Note en Réponse (Projet OPA ADVANTECH)
BRIEF published on 11/26/2024 at 18:00, 1 year 5 months ago Nombre d'actions et droits de vote d'AURES Technologies au 1er novembre Droits De Vote Actions Euronext Growth AURES Technologies Advantech
BRIEF published on 11/26/2024 at 18:00, 1 year 5 months ago Number of shares and voting rights of AURES Technologies as of November 1 Voting Rights Actions Euronext Growth AURES Technologies Advantech
PRESS RELEASE published on 11/26/2024 at 17:55, 1 year 5 months ago Nombre d'actions et droits de vote au 1er novembre AURES Technologies communique sur le nombre d'actions et de droits de vote au 1er novembre 2024, conformément aux régulations en vigueur. Détails sur l'évolution des droits de vote théoriques et exerçables Droits De Vote Actions Euronext Growth AURES Technologies ADVANTECH-AURES
BRIEF published on 11/15/2024 at 18:00, 1 year 6 months ago Baisse du Chiffre d'Affaires pour AURES au 3ème Trimestre 2024 Chiffre D'affaires Innovation Technologique AURES Technologies Réduction Activité Partenariat ADVANTECH
BRIEF published on 11/15/2024 at 18:00, 1 year 6 months ago AURES Revenue Drops in the 3rd Quarter of 2024 Technological Innovation Turnover AURES Technologies Reduction In Activity ADVANTECH Partnership
PRESS RELEASE published on 11/15/2024 at 17:55, 1 year 6 months ago AURES: Chiffre d'Affaires 3ème trimestre 2024 AURES Technologies subit une baisse d'activité de 19,19% au T3 2024, affecté par les crises et l'inflation. Le chiffre d'affaires annuel diminue de 9,87%. Stratégie de restructuration et nouveaux produits annoncés Restructuration Nouveaux Produits AURES Technologies Advantech Baisse D'activité
BRIEF published on 11/05/2024 at 18:05, 1 year 6 months ago Correction of the 2024 Half-Year Results of AURES TECHNOLOGIES Financial Results Turnover AURES Technologies Advantech Net Debt
Published on 05/23/2026 at 19:45, 9 hours 57 minutes ago Golden Minerals Announces Closing of Equity Financing
Published on 05/23/2026 at 03:15, 1 day 2 hours ago UraniumX Approved for Trading on the OTCQB Venture Market and Announces Board Change
Published on 05/23/2026 at 03:00, 1 day 2 hours ago Battery X Metals Reports Up to ~84 km Estimated Driving Range Increase Across Multiple BYD Electric Vehicles Following Next-Generation Patent-Pending Lithium-Ion Battery Rebalancing Trials, Demonstrating Performance Improvement Across the World’s Larges
Published on 05/23/2026 at 02:25, 1 day 3 hours ago Battery X Metals Announces up to $2 Million Private Placement Financing and Initiative to Strengthen Balance Sheet
Published on 05/23/2026 at 02:25, 1 day 3 hours ago Bolt Metals Completes 402 line-km MobileMT Survey at Northwind Property, Quebec
Published on 05/24/2026 at 05:35, 6 minutes ago CGTN: Xizang at 75: Development and culture create a 'miracle on Earth'
Published on 05/23/2026 at 16:30, 13 hours 11 minutes ago HiFS 2026: Upgrading Four Major Digital Finance Solutions to Accelerate Financial Institutions Toward Agentic Banking
Published on 05/23/2026 at 15:57, 13 hours 45 minutes ago EQS-Adhoc: Delivery Hero confirms approach by Uber Technologies’ with respect to potential takeover offer
Published on 05/22/2026 at 22:05, 1 day 7 hours ago Abivax présente ses résultats financiers du T1 2026 et les données à trois ans de l’étude 108, un essai d’extension ouvert de phase 2a/2b évaluant l’obéfazimod après réduction de dose dans la RCH
Published on 05/22/2026 at 22:05, 1 day 7 hours ago Abivax Presents Q1 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with UC
Published on 05/22/2026 at 19:35, 1 day 10 hours ago PROJET D'EVOLUTION DE SA GOUVERNANCE ET LA NOMINATION D'UN PRESIDENT DU DIRECTOIRE PAR INTERIM
Published on 05/22/2026 at 18:05, 1 day 11 hours ago Déclaration hebdomadaire d'opérations effectuées du 18 au 22 mai 2026
Published on 05/22/2026 at 18:05, 1 day 11 hours ago Disclosure of transactions in own shares from May 18 to May 22, 2026
Published on 05/22/2026 at 12:52, 1 day 16 hours ago Communiqué du Conseil d’administration – Assemblée Générale du 22 mai 2026
Published on 05/22/2026 at 12:52, 1 day 16 hours ago Release from the Board of Directors - Shareholders’ Meeting of May 22, 2026
